Proactive - Interviews for investors

Trust Stamp President Andrew Gowasack and Karl Falk, CEO of Botdoc joined Steve Darling from Proactive to announce an exciting new partnership. The collaboration aims to integrate Trust Stamp’s low-code Orchestration Platform into Botdoc Connect product, enhancing Identity Verification and Know Your Customer processes. This integration will include document validation using the Driver License Data Verification System provided by the American Association of Motor Vehicle Administrators. Trust Stamp has obtained a license from AAMVA to access this system, ensuring accurate and reliable identity verification. Trust Stamp and Botdoc have a history of working together in various industries, including banking, le...

First Phosphate Corp CEO John Passalacqua Chief Geologist Gilles Laverdiere joined Steve Darling from Proactive to announce that all results from the drilling program at its Bégin-Lamarche project are now available. The 99-hole drill program, totaling 25,929 meters, has uncovered a significant high-quality igneous phosphate deposit. The drilling has shown continuous phosphate mineralization over a length of 2,400 meters, spread across three mineralized zones. Laverdiere explained that a NI 43-101 resource estimate is currently underway and will be immediately followed by a Preliminary Economic Assessment. A total of 23 drill holes were completed in the Mountain Zone, totaling 5,023 meters. The Mountain Zone e...

Proactive's William Farrington takes Stephen Gunnion through the latest developments in the cryptocurrency market. Key drivers this week included the Mt. Gox repayment schedule and the Bitcoin 2024 conference. The Mt. Gox repayment schedule, from the collapsed cryptocurrency exchange in 2014, saw $8 billion worth of customer funds finally being returned to creditors. This repayment could potentially cause selling pressure on Bitcoin if converted to fiat currency. Additionally, the Bitcoin 2024 conference featured Donald Trump as a keynote speaker, who may propose policies impacting the cryptocurrency market. Bitcoin spot prices reacted positively, rising by 5% week-on-week and 8.8% month-on-month, currently trading at approximately $67,200. Ethereum ETFs, which...

The FTSE 100 jumped at the open, buoyed by strong results from Natwest and Rightmove and shrugging off a tech-sector sell-off in the US that carried through to the Asian markets this morning. In the first half hour of trade, the blue-chip index added three-quarters of a percent to 8,248. NatWest's shares jumped close to 7% after it said it expects full-year income to be ahead of its original forecast after a strong first-half performance, with the second quarter seeing close to every key metric beating guidance. Meanwhile, Metro Bank lifted 3% after it confirmed the sale of its residential mortgage book to NatWest...

Cyprium Metals Ltd (ASX:CYM, OTC:CYPMF) executive chair Matt Fifield is back in the Proactive studio to discuss a pivotal partnership with mining giant Glencore, set to resurrect production at the Nifty copper complex in Western Australia. The milestone collaboration, which includes a cathode offtake term sheet, aims to ensure transparent pricing and access to global markets, mitigating risks for Cyprium and allowing the company to focus on executing its copper strategy. What’s more, Fifield explains the contract provides revenue certainty during Nifty's initial phases and includes provisions for accepting off-spec cathode materials at Glencore’s Townsville refinery. In a...

Tryptamine Therapeutics Ltd (ASX: TYP) president and chief scientific officer Jim Gilligan joins Jonathan Jackson in the Proactive studio to discuss the company’s Phase 2a clinical trial at Massachusetts General Hospital (MGH) in the US, targeting the treatment of Irritable Bowel Syndrome (IBS). The trial involves administering oral psilocybin, known as TRP-8802, combined with psychotherapy. MGH, part of the Mass General Brigham health system and Harvard's oldest hospital, is participating in this study for the first time. Up to ten patients will receive the treatment, with primary efficacy endpoints focused on reducing chronic abdominal pain and visceral tenderness. Results ar...

North Bay Resources CEO Jared Lazerson joined Steve Darling from Proactive to provide an operational update on the company's recent acquisition, the Mt. Vernon Gold Mine. Situated in Sierra County, California, near Lake Tahoe, the mine is set to integrate with North Bay's existing 100-ton-per-day gold mill in Inyo County. Crews are gearing up to commence underground operations next week, focusing on sampling and confirmatory work. The mine features a tunnel extending approximately 150 feet, where channel sampling will be conducted on both its north and south faces. Assays from 2023 have indicated that the main zone contains over one ounce of...

Doubleview Gold Corp CEO Farshad Shirvani joined Steve Darling from Proactive to announce the maiden Mineral Resource Estimate for the Hat project in northwestern British Columbia, emphasizing the project's major contents of copper, cobalt, and the potential for scandium. Shirvani highlighted that the company has made extensive efforts since 1993, with significant progress since 2011, marking a transition from exploration to mining development—a major milestone for its shareholders. The Hat project currently reports 627 million tonnes of indicated resources and 477 million tonnes of inferred resources, which together represent only 15% of the explored area. The focus on high-grade material has resulted in an es...

Paul Barrett, the newly appointed CEO of Rome Resources and formerly the Executive Director of Pathfinder Minerals, spoke with Steve Darling from Proactive about Pathfinder Minerals' recent strategic moves. Previously operating as a cash shell company, Pathfinder Minerals disposed of its asset in Mozambique and has been actively searching for a new venture. The company has now merged with Rome Resources, which owns a high-grade tin project located in the Democratic Republic of Congo (DRC). Barrett revealed that the merged entity will operate under the name Rome Resources and is scheduled to be listed on AIM with the ticker RMR...

Lisata Therapeutics Inc chief medical officer Kristen Buck discusses the company's research collaboration with Haystack Oncology to evaluate the efficacy of certepetide with Proactive's Stephen Gunnion. Buck explained that certepetide is a nine amino acid cyclic peptide designed to target up-regulated receptors on solid tumors, enhancing the delivery of anti-cancer therapies. She highlighted the challenges in treating pancreatic cancer, such as its hostile microenvironment and late-stage detection. Buck detailed the collaboration with Haystack Oncology, emphasizing the use of their minimal residual disease (MRD) technology to detect circulating tumor DNA in blood, which can indicate cancer recurrence or progression. This technology...